Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial
PaperCitations, authors & open-access status
Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 200 citations, 2023 year and green oa status.
200
Citations
2023
Year
green
OA Status